NGM Biopharmaceuticals, NGM is showing recent insider trading activity. Public SEC records indicate that GROUP COLUMN recently Bought $3,627 worth of shares on 4 days ago. With that said, our editors here at politicsandwallstreet.com, are adding NGM to our watchlist to see if this momentum continues.
Based on this transaction and a few others from Corporate Insiders of NGM that Sold 124,338,768 worth of shares in the last 3 months, the Insider Confidence level of NGM Biopharmaceuticals is trending Down.
Since these insiders have unique insights into what's happening at NGM Biopharmaceuticals, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for NGM:
In addition, TradingView issued a Sell rating for NGM over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook.
Ritu Baral
Here is a bit more on NGM Biopharmaceuticals, NGM but please do your own research.
NGM Summary: NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc. is based in San Francisco, California.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to NGM, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Based on this transaction and a few others from Corporate Insiders of NGM that Sold 124,338,768 worth of shares in the last 3 months, the Insider Confidence level of NGM Biopharmaceuticals is trending Down.
Since these insiders have unique insights into what's happening at NGM Biopharmaceuticals, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for NGM:
- GROUP COLUMN - director, 10 percent owner:, Bought $3,627 worth of shares on 4 days ago
- GROUP COLUMN - director, 10 percent owner:, Bought $3,627 worth of shares on 4 days ago
- DAVID GOEDDEL - director, 10 percent owner:, Bought $3,627 worth of shares on 4 days ago
- DAVID GOEDDEL - director, 10 percent owner:, Bought $907 worth of shares on 4 days ago
In addition, TradingView issued a Sell rating for NGM over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook.
Ritu Baral
Here is a bit more on NGM Biopharmaceuticals, NGM but please do your own research.
NGM Summary: NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc. is based in San Francisco, California.
- Recent Last Price: $0.63
- Price Change: $0.03, 4.43%
- Yearly Gain: -88.02%
- Market Cap: $49.65M
- P/E Ratio: -0.326
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to NGM, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
